Status:
WITHDRAWN
Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.
Lead Sponsor:
Heidelberg University
Collaborating Sponsors:
Dietmar Hopp Stiftung
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
15-80 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to evaluate if retarded phosphatidylcholine is as effective as mesalazin in preventing an acute episode in ulcerative colitis. The hypothesis is, that ulcerative colitis ...
Eligibility Criteria
Inclusion
- diagnosis of ulcerative colitis in remission (CAI 3 or less)
- signed letter of content
- no steroids or immunosupressants in the last 6 weeks
- at least 5 relapses in the last 3 years
- last relapse was 8 months ago or less
- complete colonoscopy at entry
Exclusion
- pregnancy or breast feeding
- steroids or immunosuppressants
- acute episode of UC
- condition after complete or partial colektomy
- known intolerance to mesalazin
- severe medical disease other than colitis
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00259571
End Date
March 1 2010
Last Update
December 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Hospital - University of Heidelberg
Heidelberg, Germany, 69120